1-3 of 3
Arthur P. Decillis, MD
Close
Sort by
Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 3937.
https://doi.org/10.1182/blood-2019-121736
Published: 2019
Journal Articles

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Jennifer R Brown, MD, PhD, Matthew S. Davids, MD, Jordi Rodon, MD, Pau Abrisqueta, MD, Arthur P. DeCillis, MD, MS, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Farrukh T Awan, MD, MS
Journal: Blood
Blood (2011) 118 (21): 2683.
https://doi.org/10.1182/blood.V118.21.2683.2683
Published: 2011
Journal Articles

Major Cytogenetic Responses to BMS-354825 in Patients with Chronic Myeloid Leukemia Are Associated with a One to Two Log Reduction in BCR-ABL Transcript.

Neil P. Shah, MD, PhD, Susan Branford, Timothy P. Hughes, MD, John M. Nicoll, Arthur P. Decillis, MD, Charles L. Sawyers, MD.
Journal: Blood
Blood (2004) 104 (11): 1008.
https://doi.org/10.1182/blood.V104.11.1008.1008
Published: 2004